Challenges in Overcoming Advanced-stage or Relapsed Refractory Extranodal NK/T-cell Lymphoma: Meta-analysis of Individual Patient Data

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Aug 15

PMID 39144825

Authors

Tong Yoon Kim

Tae Jung Kim

Eun Ji Han

Gi June Min

Youngwoo Jeon

Seok-Goo Cho

Affiliations

Soon will be listed here.

Abstract

Introduction: Extranodal NK/T-cell lymphoma (ENKTCL), a non-Hodgkin lymphoma, is known for its destructive local impact on nasal structures and systemic induction of inflammatory cytokines. Concurrent treatment with radiation and nonanthracycline- based chemotherapy has improved survival rates in patients with localized disease stages. However, survival outcomes vary significantly in advanced-stage and relapsed or refractory (R/R) cases.

Methods: Therefore, we conducted a meta-analysis using random effects models to assess prognostic factors in advanced or R/R ENKTCL, employing a digital extractor on Kaplan-Meier graphs owing to the scarcity of published prospective trials for these patients.

Results: We observed that patients with advanced ENKTCL treated with Lasparaginase had a median progression-free survival (PFS) of 14.3 months and an overall survival (OS) of 19 months. In R/R ENKTCL, PFS and OS were 11.7 and 15.6 months, respectively. Additionally, OS outcomes in advanced-stage ENKTCL were better in the asparaginase group than that in the non-asparaginase group, with PEG-asparaginase showing superior results compared with that using Lasparaginase. Epstein-Barr Virus (EBV)-DNA positivity in the bloodstream prior to treatment was associated with poor outcomes in advanced-stage ENKTCL, and similar trends were observed in patients with R/R ENKTCL and post-treatment EBV viremia.

Discussion: Collectively, these findings suggest that chemotherapy with Lasparaginase or PEG-asparaginase can enhance survival in advanced or R/R ENKTCL. However, future strategies must be developed to effectively suppress EBV viremia and achieve a deep response toward tumor eradication.

References

Kim G, Lee S, Chang S, Park H, Pyo H, Kim J . Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol. 2001; 61(3):261-9. DOI: 10.1016/s0167-8140(01)00428-5. View

Li J, Li Y, Zhong M, Liu X, Li J, Li K . Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study. Eur J Haematol. 2017; 100(3):247-256. DOI: 10.1111/ejh.13004. View

Moskowitz C, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock C . Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010; 28(11):1896-903. PMC: 3651601. DOI: 10.1200/JCO.2009.26.5942. View

Zhou Z, Li X, Chen C, Li X, Zhang L, Li L . Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014; 93(11):1889-94. DOI: 10.1007/s00277-014-2136-7. View

Yamaguchi M, Kwong Y, Kim W, Maeda Y, Hashimoto C, Suh C . Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011; 29(33):4410-6. DOI: 10.1200/JCO.2011.35.6287. View

Jeong S, Song H, Park J, Yang D, Koh Y, Yoon S . Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. Biol Blood Marrow Transplant. 2018; 24(12):2471-2478. DOI: 10.1016/j.bbmt.2018.07.034. View

Cho S, Kim N, Sohn H, Lee S, Oh S, Lee H . Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs. Mol Ther. 2015; 23(8):1401-1409. PMC: 4817864. DOI: 10.1038/mt.2015.91. View

Li Y, Yao B, Jin J, Wang W, Liu Y, Song Y . Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2005; 24(1):181-9. DOI: 10.1200/JCO.2005.03.2573. View

Kanate A, DiGilio A, Ahn K, Al Malki M, Jacobsen E, Steinberg A . Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br J Haematol. 2017; 182(6):916-920. PMC: 5796874. DOI: 10.1111/bjh.14879. View

10.

Kim B, Kim D, Im S, Kim C, Kim T, Yoon S . Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol. 2008; 20(1):121-8. DOI: 10.1093/annonc/mdn551. View

11.

Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F . Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2010; 117(6):1834-9. DOI: 10.1182/blood-2010-09-307454. View

12.

Wei Y, Liu W, Qi F, Zhang C, Zheng B, Xie Y . Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study. Ann Hematol. 2023; 103(1):163-174. DOI: 10.1007/s00277-023-05455-4. View

13.

Hu S, Lin N, Liu J, Sun Y, Liu W, Wang X . A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma. Front Oncol. 2022; 12:839252. PMC: 8916231. DOI: 10.3389/fonc.2022.839252. View

14.

Hari P, Raj R, Olteanu H . Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. N Engl J Med. 2016; 375(15):1501-1502. DOI: 10.1056/NEJMc1605684. View

15.

McKelvie P, Climent F, Krings G, Hasserjian R, Abramson J, Pilch B . Small-cell predominant extranodal NK/T cell lymphoma, nasal type: clinicopathological analysis of a series of cases diagnosed in a Western population. Histopathology. 2016; 69(4):667-79. DOI: 10.1111/his.12990. View

16.

Lee K, Yun T, Kim D, Im S, Kim T, Yoon S . First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2006; 47(7):1274-82. DOI: 10.1080/10428190600562823. View

17.

Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T . Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. J Clin Oncol. 2016; 35(1):32-39. DOI: 10.1200/JCO.2016.68.1619. View

18.

Balduzzi S, Rucker G, Schwarzer G . How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019; 22(4):153-160. PMC: 10231495. DOI: 10.1136/ebmental-2019-300117. View

19.

Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T . Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995; 76(11):2351-6. DOI: 10.1002/1097-0142(19951201)76:11<2351::aid-cncr2820761125>3.0.co;2-1. View

20.

Huang H, Zhu J, Yao M, Kim T, Yoon D, Cho S . Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. J Hematol Oncol. 2021; 14(1):25. PMC: 7885403. DOI: 10.1186/s13045-020-01020-y. View